Yıl: 2021 Cilt: 10 Sayı: 1 Sayfa Aralığı: 109 - 118 Metin Dili: Türkçe DOI: 10.5336/pharmsci.2020-76878 İndeks Tarihi: 01-10-2021

Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?

Öz:
İlaç hatalarının artması sonucunda, sağlık harcamaları da artmakta ve hasta sonuçları kötüleşebilmektedir. Klinik eczacılar, sağlıkekibine katılarak ve özellikle ilaç kullanımı ile ilgili sorumlulukları paylaşarak ilaçla ilgili sorunların belirlenmesi ve önlenmesi konusundafayda sağlamaktadırlar. Yaklaşık 60 yıl önce Amerika Birleşik Devletleri’nde klinik eczacılık uzmanlığı tanımlanmıştır ve şu anda birçok ülkenin sağlık sisteminde klinik eczacılık uygulamaları mevcuttur. Klinikeczacılık, hizmetlerinde farmasötik bakım felsefesini benimsemektedir ve birincil amaç olarak en ideal hasta sonuçlarının elde edilmesiniamaçlamaktadır. Klinik eczacılık hizmetleri, hastaneler, serbest eczaneler, poliklinikler, bakım evleri, evde bakım hizmetleri gibi sağlık hizmeti sunulan tüm ortamlarda verilebilmektedir. Klinik eczacılıkhizmetleri; ilaç danışmanlığı ve hasta eğitimi hizmeti, kapsamlı ilaç yönetimi, ilaç uzlaşısı, ilaç incelemesi, ilaçla ilişkili sorunların saptanması ve önlenmesi, tedavi izlemi ve koruyucu sağlık hizmetleri gibibazı ana konu başlıklarında incelenebilir. Klinik eczacının kim olduğuna odaklanan bu derlemede, klinik eczacılığın genel konsepti ve klinik eczacılık eğitimi, çalışma alanları ve sunulan hizmetlerözetlenmiştir. Bu derlemenin ülkemizdeki klinik eczacılık hizmetlerinin uygulanması ve geliştirilmesi sırasında araştırmacılar, uygulayıcılar ve sağlık sistemi geliştiricileri için yararlı bir kaynak olmasıbeklenmektedir.
Anahtar Kelime:

A Question Awaiting Answer During the Development and Implementation Stage of Clinical Pharmacy Services in Turkey: Who is Clinical Pharmacist?

Öz:
There are concerns regarding an increase in medication error that could be resulted in high health costs and poor patient outcomes. Clinical pharmacists would be a beneficial impact on the prevention and detection of medication-related problems by involving the health care team and sharing responsibilities, especially about medication utilization. Almost sixty years ago, specialization in clinical pharmacy was defined in the United States of America and currently available in the health-system of many countries. Clinical pharmacy adopts the philosophy of pharmaceutical care in its services and aims to achieve the most ideal patients’ clinical outcomes as the primary purpose. Clinical pharmacy services can be provided in all healthcare settings such as hospitals, community pharmacies, outpatient clinics, nursing homes, home care services. Clinical pharmacy services can be sorted in some major topics, such as drug information, patient counseling and education, comprehensive medication management, medication reconciliation, medication review, prevention and detection of medication-related problems, therapeutic drug monitoring, and preventive health services. Focusing on who the clinical pharmacist is, this review was summarized the general concept of clinical pharmacy and clinical pharmacists’ education, workplace, and services. This review is expected to be a useful resource for researchers and practitioners and health care system developers during the implementation and development of clinical pharmacy services in our country.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Institute of Medicine (US) Committee on Quality of Health Care in America. To Err is Human: Building a Safer Health System. Kohn LT, Corrigan JM, Donaldson MS, eds. Washington (DC): National Academies Press (US); 2000. [PubMed]
  • 2. Biles JA. The doctor of pharmacy. JAMA. 1983;249(9):1157-60. [Crossref] [PubMed]
  • 3. Jacobi J. Clinical pharmacists: practitioners who are essential members of your clinical care team. Revista Médica Clínica Las Condes. 2016;27(5):571-7. [Crossref]
  • 4. Carter BL. Evolution of Clinical Pharmacy in the USA and Future Directions for Patient Care. Drugs Aging. 2016;33(3):169-77. [Crossref] [PubMed] [PMC]
  • 5. American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816-7. [Crossref] [PubMed]
  • 6. Hazen ACM, de Bont AA, Boelman L, zwart DLM, de gier JJ, de Wit NJ, et al. The degree of integration of non-dispensing pharmacists in primary care practice and the impact on health outcomes: A systematic review. Res Social Adm Pharm. 2018;14(3):228-240. [Crossref] [PubMed]
  • 7. Soares IB, Imfeld-Isenegger TL, Makovec UN, Horvat N, Kos M, Arnet I, et al. A survey to assess the availability, implementation rate and remuneration of pharmacist-led cognitive services throughout Europe. Res Social Adm Pharm. 2020;16(1):41-7. [Crossref] [PubMed]
  • 8. Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Des. 2004;10(31): 3987-4001. [Crossref] [PubMed]
  • 9. The European Society of Clinical Pharmacy [İnternet]. [Erişim tarihi: 16.04.2020]. What is Clinical Pharmacy?. Erişim linki: [Link] 10. Swiss Association of Public Health Administration and Hospital Pharmacists [İnternet]. © gSASA - Alle Rechte vorbehalten | Site by WeServe Ag [Erişim tarihi: 16.04.2020]. Definition de la pharmacie clinique hospitalie ́ re ̀ selon la gSASA. Erişim linki: [Link]
  • 11. Canadian Society of Hospital Pharmacist [İnternet]. [Erişim Tarihi: 17.04.2020]. Clinical Pharmacy. Erişim linki: [Link]
  • 12. T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu [İnternet]. [Erişim tarihi: 18.04.2020]. İyi eczacilik uygulamalari kilavuzu. Erişim linki: [Link]
  • 13. T.C. Sağlık Bakanlığı Eczacılıkta Uzmanlık Kurulu [İnternet]. [Erişim tarihi: 18.04.2020]. Klinik eczacılık uzmanlık eğitimi çekirdek müfredatı. Erişim linki: [Link]
  • 14. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955-64. [Crossref] [PubMed]
  • 15. Aypar E, Sancar M, Izzettin FV. Eczacılıkta yeni dönem: Klinik eczacılık ve sağlık sistemindeki yeri [New era in pharmacy: Its place in clinical pharmacy and health system]. Sağlık Düşüncesi ve Tıp Kültürü Dergisi. 2014;30:48- 51. [Link]
  • 16. American College of Clinical Pharmacy. Standards of practice for clinical pharmacists. Pharmacotherapy. 2014;34(8):794-7. [Crossref] [PubMed]
  • 17. Canadian Pharmacist Association [İnternet]. © 2020 CPhA. All Rights Reserved [Erişim tarihi: 18.04.2020]. Pharmacist in Canada. Erişim linki: [Link]
  • 18. Australian government Department of Health [İnternet]. © Commonwealth of Australia [Erişim tarihi: 19.04.2020]. Home medicines review program qualitative research project final report. Erişim linki: [Link]
  • 19. National Health Service [İnternet]. © Crown copyright [Erişim tarihi: 19.04.2020]. New Medicine Service (NMS). Erişim linki: [Link]
  • 20. Akazawa M, Nomura K, Kusama M, Igarashi A. Drug Utilization Reviews by Community Pharmacists in Japan: Identification of Potential Safety Concerns through the Brown Bag Program. Value Health Reg Issues. 2012;1(1): 98-104. [Crossref] [PubMed]
  • 21. ASHP Early Years [İnternet]. © Copyright 2020 American Society of Health-System Pharmacists [Erişim tarihi: 29.05.2020]. American Society of Health-System Pharmacists. Erişim linki: [Link]
  • 22. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists' effect as team members on patient care: systematic review and metaanalyses. Med Care. 2010;48(10):923-33. [Crossref] [PubMed]
  • 23. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(3):CD000336. Update in: Cochrane Database Syst Rev. 2010;(7):CD000336. [Crossref] [PubMed] [PMC]
  • 24. Tett SE, Higgins gM, Armour CL. Impact of pharmacist interventions on medication management by the elderly: a review of the literature. Ann Pharmacother. 1993;27(1):80-6. [Crossref] [PubMed]
  • 25. Jenkins MH, Bond CA. The impact of clinical pharmacists on psychiatric patients. Pharmacotherapy. 1996;16(4):708-14. [PubMed]
  • 26. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29(5): 691-8. [Crossref] [PubMed]
  • 27. Schumock gT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical pharmacy services--1988-1995. The Publications Committee of the American College of Clinical Pharmacy. Pharmacotherapy. 1996; 16(6):1188-208. [PubMed]
  • 28. Pickard AS, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. Ann Pharmacother. 1999;33(11):1167-72. [Crossref] [PubMed] 29. Pedersen CA, Schneider PJ, Santell JP. ASHP national survey of pharmacy practice in hospital settings: prescribing and transcribing-- 2001. Am J Health Syst Pharm. 2001;58(23): 2251-66. [Crossref] [PubMed]
  • 30. Chen EYH, Wang KN, Sluggett JK, Ilomäki J, Hilmer SN, Corlis M, et al. Process, impact and outcomes of medication review in Australian residential aged care facilities: A systematic review. Australas J Ageing. 2019;38 Suppl 2:9-25. [Crossref] [PubMed]
  • 31. Doherty RB, Crowley RA; Health and Public Policy Committee of the American College of Physicians. Principles supporting dynamic clinical care teams: an American College of Physicians position paper. Ann Intern Med. 2013;159(9):620-6. [PubMed]
  • 32. İzzettin FV. A model for the ımplementation of patient-oriented pharmacy education: clinical pharmacy and pharmaceutical care courses. günay D, öztemel E, editörler. Uluslararası Yükseköğretim Kongresi: Yeni Yönelişler ve Sorunlar (UYK-2011); 27-29 Mayıs 2011; İstanbul, Türkiye. Has Matbaacılık; 2011. p.317- 23.
  • 33. Umar RM, Apikoglu-Rabus S, Yumuk PF. Significance of a clinical pharmacist-led comprehensive medication management program for hospitalized oncology patients. Int J Clin Pharm. 2020;42(2):652-61. [Crossref] [PubMed]
  • 34. Kucuk E, Bayraktar-Ekincioglu A, Erman M, Kilickap S. Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. J Oncol Pharm Pract. 2020; 26(3):595-602. [Crossref] [PubMed]
  • 35. Ertuna E, Arun Mz, Ay S, Koçak FöK, gökdemir B, İspirli g. Evaluation of pharmacist interventions and commonly used medications in the geriatric ward of a teaching hospital in Turkey: a retrospective study. Clin Interv Aging. 2019;14:587-600. [Crossref] [PubMed] [PMC]
  • 36. Yalçin N, Ak S, gürel şC, çeliker A. Compliance in schizophrenia spectrum disorders: the role of clinical pharmacist. Int Clin Psychopharmacol. 2019;34(6):298-304. [Crossref] [PubMed]
  • 37. Izzettin FV, Celik S, Acar RD, Tezcan S, Aksoy N, Bektay MY, et al. The role of the clinical pharmacist in patient education and monitoring of patients under warfarin treatment. Journal of Research in Pharmacy. 2019;23(6): 1057-163. [Crossref]
  • 38. Kara E, İnkaya Aç, Aydın Haklı D, Demirkan K, Ünal S. Polypharmacy and drugrelated problems among people living with HIV/AIDS: a single-center experience. Turk J Med Sci. 2019;49(1):222-9. [Crossref] [PubMed] [PMC]
  • 39. Tecen-Yucel K, Bayraktar-Ekincioglu A, Kilickap S, Erman M. Clinical pharmacy practices in oncology patients treated with tyrosine kinase inhibitors. International Journal of Hematology and Oncology. 2018;28(4):053-60. [Link]
  • 40. Izzettin FV, Al-taie A, Sancar M, Aliustaoglu M. Influence of pharmacist recommendations for chemotherapy-related problems in diabetic cancer patients. Marmara Pharmaceutical Journal. 2017;21(3):603-11. [Crossref]
  • 41. Tezcan S, İzzettin FV, Sancar M, Turhal NS, Yumuk PF. Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer. Eur J Hosp Pharm. 2018;25(e1):e17-e20. [Crossref] [PubMed] [PMC]
  • 42. Selcuk A, Sancar M, Okuyan B, Demirtunc R, Izzettin FV. The potential role of clinical pharmacists in elderly patients during hospital admission. Pharmazie. 2015;70(8):559-62. [PubMed]
  • 43. Sancar M, Sirinoglu Y, Okuyan B, Karagoz T, Izzettin FV. The effect of pharmacist-led education on inhaler use skills in hospitalised patients with chronic obstructive pulmonary disease. Eur J Hosp Pharm. 2015;22(6):366- 8. [Crossref]
  • 44. Turnacilar M, Sancar M, Apikoglu-Rabus S, Hursitoglu M, Izzettin FV. Improvement of diabetes indices of care by a short pharmaceutical care program. Pharm World Sci. 2009; 31(6):689-95. [Crossref] [PubMed]
  • 45. Clark PM, Karagoz T, Apikoglu-Rabus S, Izzettin FV. Effect of pharmacist-led patient education on adherence to tuberculosis treatment. Am J Health Syst Pharm. 2007;64(5): 497-505. [Crossref] [PubMed]
  • 46. Amundstuen Reppe L, Spigset O, Schjøtt J. Drug Information Services Today: Current Role and Future Perspectives in Rational Drug Therapy. Clin Ther. 2016;38(2):414-21. [Crossref] [PubMed]
  • 47. ghaibi S, Ipema H, gabay M; American Society of Health System Pharmacists. ASHP guidelines on the pharmacist's role in providing drug information. Am J Health Syst Pharm. 2015;72(7):573-7. [Crossref] [PubMed]
  • 48. Bonetti AF, Reis WC, Lombardi NF, Mendes AM, Netto HP, Rotta I, et al. Pharmacist-led discharge medication counselling: A scoping review. J Eval Clin Pract. 2018;24(3):570-9. [Crossref] [PubMed]
  • 49. Salvo MC, Cannon-Breland ML. Motivational interviewing for medication adherence. J Am Pharm Assoc (2003). 2015;55(4):e354-61; quiz e362-3. [Crossref] [PubMed]
  • 50. Doucette WR, Farris KB, Youland KM, Newland BA, Egerton SJ, Barnes JM. Development of the Drug Adherence Work-up (DRAW) tool. J Am Pharm Assoc (2003). 2012;52(6): e199-204. [Crossref] [PubMed]
  • 51. Lehmann A, Aslani P, Ahmed R, Celio J, gauchet A, Bedouch P, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36(1):55-69. [Crossref] [PubMed]
  • 52. Okumura LM, Rotta I, Correr CJ. Assessment of pharmacist-led patient counseling in randomized controlled trials: a systematic review. Int J Clin Pharm. 2014;36(5):882-91. [Crossref] [PubMed]
  • 53. Nester TM, Hale LS. Effectiveness of a pharmacist-acquired medication history in promoting patient safety. Am J Health Syst Pharm. 2002;59(22):2221-5. [Crossref] [PubMed]
  • 54. Lipton HL, Bird JA. The impact of clinical pharmacists' consultations on geriatric patients' compliance and medical care use: a randomized controlled trial. gerontologist. 1994;34(3): 307-15. [Crossref] [PubMed]
  • 55. Proia KK, Thota AB, Njie gJ, Finnie RK, Hopkins DP, Mukhtar Q, et al; Community Preventive Services Task Force. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47(1):86-99. [Crossref] [PubMed] [PMC]
  • 56. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168(7):687-94. [Crossref] [PubMed]
  • 57. Al-Hashar A, Al-zakwani I, Eriksson T, Sarakbi A, Al-zadjali B, Al Mubaihsi S, et al. Impact of medication reconciliation and review and counselling, on adverse drug events and healthcare resource use. Int J Clin Pharm. 2018;40(5):1154-64. [Crossref] [PubMed]
  • 58. Viswanathan M, Kahwati LC, golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76-87. [Crossref] [PubMed]
  • 59. Developed through the ASHP Council on Pharmacy Practice and approved by the ASHP Board of Directors on April 13, 2012, and by the ASHP House of Delegates on June 10, 2012. ASHP statement on the pharmacist's role in medication reconciliation. Am J Health Syst Pharm. 2013;70(5):453-6. [Crossref] [PubMed]
  • 60. Mekonnen AB, McLachlan AJ, Brien JA. Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41(2):128-44. [Crossref] [PubMed]
  • 61. griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF, et al. PCNE definition of medication review: reaching agreement. Int J Clin Pharm. 2018;40(5): 1199-1208. [Crossref] [PubMed]
  • 62. Ibrahim KH, gunderson B, Rotschafer JC. Intensive care unit antimicrobial resistance and the role of the pharmacist. Crit Care Med. 2001;29(4 Suppl):N108-13. [Crossref] [PubMed]
  • 63. Chuang LC, Sutton JD, Henderson gT. Impact of a clinical pharmacist on cost saving and cost avoidance in drug therapy in an intensive care unit. Hosp Pharm. 1994;29(3):215-8, 221. [PubMed]
  • 64. Leache L, Aquerreta I, Aldaz A, Monedero P, Idoate A, Ortega A. Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients. Res Social Adm Pharm. 2020;16(9):1285-9. [Crossref] [PubMed]
  • 65. gentry CA, greenfield RA, Slater LN, Wack M, Huycke MM. Outcomes of an antimicrobial control program in a teaching hospital. Am J Health Syst Pharm. 2000;57(3):268-74. [Crossref] [PubMed]
  • 66. Dooley MJ, Allen KM, Doecke CJ, galbraith KJ, Taylor gR, Bright J, et al. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. Br J Clin Pharmacol. 2004;57(4):513-21. [Crossref] [PubMed] [PMC]
  • 67. Pharmacy Intervention in the Medication-use Process [İnternet]. [Erişim tarihi: 18.04.2020]. International Pharmaceutical Federation (FIP). Erişim linki: [Link]
  • 68. Jeong S, Lee M, Ji E. Effect of pharmaceutical care interventions on glycemic control in patients with diabetes: a systematic review and meta-analysis. Ther Clin Risk Manag. 2018; 14:1813-29. [Crossref] [PubMed] [PMC]
  • 69. Niznik JD, He H, Kane-gill SL. Impact of clinical pharmacist services delivered via telemedicine in the outpatient or ambulatory care setting: A systematic review. Res Social Adm Pharm. 2018;14(8):707-17. [Crossref] [PubMed]
  • 70. European Pharmacists Forum [İnternet]. © Copyright 2020 Alliance UniChem IP Limited [Erişim tarihi: 18.04.2020]. The role of pharmacy in supporting the public's health An EPF white paper and call to action. Erişim linki: [Link]
  • 71. Agomo CO. The role of community pharmacists in public health: a scoping review of the literature. Journal of Pharmaceutical Health Services Research. 2012;3(1):25-33. [Crossref]
  • 72. de With K, Allerberger F, Amann S, Apfalter P, Brodt HR, Eckmanns T, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the german Society for Infectious Diseases. Infection. 2016;44(3):395-439. [PubMed] [PMC]
  • 73. Moreira Lima gamboa M, Tesainer Brunetto A, Ferreira Dos Santos ME, gregianin L. The pharmacists' role in clinical research. Farm Hosp. 2011;35(6):341-2. [Crossref] [PubMed]
  • 74. International Pharmaceutical Federation (FIP) [İnternet]. Copyright © 2020 International Pharmaceutical Federation (FIP) [Erişim tarihi: 18.04.2020]. Advanced Practice and Specialisation in Pharmacy: global Report 2015. The Hague: International Pharmaceutical Federation; 2015. Erişim linki: [Link
APA KARA E, OKUYAN B, Demirkan K, SANCAR M (2021). Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. , 109 - 118. 10.5336/pharmsci.2020-76878
Chicago KARA Emre,OKUYAN Betül,Demirkan Kutay,SANCAR MESUT Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. (2021): 109 - 118. 10.5336/pharmsci.2020-76878
MLA KARA Emre,OKUYAN Betül,Demirkan Kutay,SANCAR MESUT Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. , 2021, ss.109 - 118. 10.5336/pharmsci.2020-76878
AMA KARA E,OKUYAN B,Demirkan K,SANCAR M Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. . 2021; 109 - 118. 10.5336/pharmsci.2020-76878
Vancouver KARA E,OKUYAN B,Demirkan K,SANCAR M Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. . 2021; 109 - 118. 10.5336/pharmsci.2020-76878
IEEE KARA E,OKUYAN B,Demirkan K,SANCAR M "Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?." , ss.109 - 118, 2021. 10.5336/pharmsci.2020-76878
ISNAD KARA, Emre vd. "Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?". (2021), 109-118. https://doi.org/10.5336/pharmsci.2020-76878
APA KARA E, OKUYAN B, Demirkan K, SANCAR M (2021). Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. Literatür Eczacılık Bilimleri Dergisi, 10(1), 109 - 118. 10.5336/pharmsci.2020-76878
Chicago KARA Emre,OKUYAN Betül,Demirkan Kutay,SANCAR MESUT Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. Literatür Eczacılık Bilimleri Dergisi 10, no.1 (2021): 109 - 118. 10.5336/pharmsci.2020-76878
MLA KARA Emre,OKUYAN Betül,Demirkan Kutay,SANCAR MESUT Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. Literatür Eczacılık Bilimleri Dergisi, vol.10, no.1, 2021, ss.109 - 118. 10.5336/pharmsci.2020-76878
AMA KARA E,OKUYAN B,Demirkan K,SANCAR M Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. Literatür Eczacılık Bilimleri Dergisi. 2021; 10(1): 109 - 118. 10.5336/pharmsci.2020-76878
Vancouver KARA E,OKUYAN B,Demirkan K,SANCAR M Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?. Literatür Eczacılık Bilimleri Dergisi. 2021; 10(1): 109 - 118. 10.5336/pharmsci.2020-76878
IEEE KARA E,OKUYAN B,Demirkan K,SANCAR M "Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?." Literatür Eczacılık Bilimleri Dergisi, 10, ss.109 - 118, 2021. 10.5336/pharmsci.2020-76878
ISNAD KARA, Emre vd. "Türkiye’de Klinik Eczacılık Hizmetlerinin Yerleştirilmesi ve Geliştirilmesi Aşamasında Cevap Bekleyen Bir Soru: Klinik Eczacı Kimdir?". Literatür Eczacılık Bilimleri Dergisi 10/1 (2021), 109-118. https://doi.org/10.5336/pharmsci.2020-76878